Although blood test reduces deaths by two for every 1,000 men screened, many could face unnecessary treatment ...

Today, the American Cancer Society (ACS) released Prostate Cancer Statistics, 2025, a report on current prostate cancer occurrence and outcomes in the United States. According to the study, prostate ...

A landmark review of nearly 800,000 men has found that PSA blood tests do reduce prostate cancer deaths — a shift from ...

Prostate cancer screening could save thousands of lives a year and should be made an option for the vast majority of men, a ...

At 25 years, the prostate cancer-specific survival rate was 94% among men with screen-detected prostate cancer who chose primary active surveillance – but prostate cancer progression rates are high.

Using de-identified data from the National Cancer Institute, researchers followed 205 patients—average age, 61 years—with prostate cancer and preexisting depression. Patients with both conditions had ...

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

A European study has demonstrated a sustained long-term reduction in prostate cancer mortality through prostate-specific antigen (PSA) screening. However, the findings also highlight the issue of ...

Men diagnosed at screening aged 50 years projected to have 16 percent chance that cancer would not have been detected within 15 years.

Excess body weight, as measured by BMI, is associated with improved overall survival (OS) in men with advanced prostate cancer, particularly those with metastatic castration-resistant disease, a ...

Most men with low-grade prostate cancer have an excellent prognosis, with a five-year survival rate of more than 99%. But ...

Most prostate cancers rely on male sex hormones, known as androgens, to grow. As a result, standard treatment focuses on ...